S&P 500   3,897.80 (+2.27%)
DOW   31,619.08 (+2.22%)
QQQ   321.30 (+2.28%)
AAPL   125.92 (+3.84%)
MSFT   236.57 (+1.80%)
FB   261.51 (+1.51%)
GOOGL   2,060.21 (+1.89%)
TSLA   715.39 (+5.91%)
AMZN   3,121.95 (+0.94%)
NVDA   547.48 (-0.20%)
BABA   239.97 (+0.93%)
CGC   35.09 (+7.15%)
GE   13.18 (+5.10%)
MU   94.11 (+2.82%)
NIO   49.56 (+8.26%)
AMD   85.41 (+1.06%)
T   28.26 (+1.33%)
F   11.98 (+2.39%)
ACB   11.32 (+7.60%)
DIS   195.67 (+3.51%)
BA   224.80 (+6.03%)
NFLX   550.43 (+2.15%)
BAC   35.63 (+2.65%)
S&P 500   3,897.80 (+2.27%)
DOW   31,619.08 (+2.22%)
QQQ   321.30 (+2.28%)
AAPL   125.92 (+3.84%)
MSFT   236.57 (+1.80%)
FB   261.51 (+1.51%)
GOOGL   2,060.21 (+1.89%)
TSLA   715.39 (+5.91%)
AMZN   3,121.95 (+0.94%)
NVDA   547.48 (-0.20%)
BABA   239.97 (+0.93%)
CGC   35.09 (+7.15%)
GE   13.18 (+5.10%)
MU   94.11 (+2.82%)
NIO   49.56 (+8.26%)
AMD   85.41 (+1.06%)
T   28.26 (+1.33%)
F   11.98 (+2.39%)
ACB   11.32 (+7.60%)
DIS   195.67 (+3.51%)
BA   224.80 (+6.03%)
NFLX   550.43 (+2.15%)
BAC   35.63 (+2.65%)
S&P 500   3,897.80 (+2.27%)
DOW   31,619.08 (+2.22%)
QQQ   321.30 (+2.28%)
AAPL   125.92 (+3.84%)
MSFT   236.57 (+1.80%)
FB   261.51 (+1.51%)
GOOGL   2,060.21 (+1.89%)
TSLA   715.39 (+5.91%)
AMZN   3,121.95 (+0.94%)
NVDA   547.48 (-0.20%)
BABA   239.97 (+0.93%)
CGC   35.09 (+7.15%)
GE   13.18 (+5.10%)
MU   94.11 (+2.82%)
NIO   49.56 (+8.26%)
AMD   85.41 (+1.06%)
T   28.26 (+1.33%)
F   11.98 (+2.39%)
ACB   11.32 (+7.60%)
DIS   195.67 (+3.51%)
BA   224.80 (+6.03%)
NFLX   550.43 (+2.15%)
BAC   35.63 (+2.65%)
S&P 500   3,897.80 (+2.27%)
DOW   31,619.08 (+2.22%)
QQQ   321.30 (+2.28%)
AAPL   125.92 (+3.84%)
MSFT   236.57 (+1.80%)
FB   261.51 (+1.51%)
GOOGL   2,060.21 (+1.89%)
TSLA   715.39 (+5.91%)
AMZN   3,121.95 (+0.94%)
NVDA   547.48 (-0.20%)
BABA   239.97 (+0.93%)
CGC   35.09 (+7.15%)
GE   13.18 (+5.10%)
MU   94.11 (+2.82%)
NIO   49.56 (+8.26%)
AMD   85.41 (+1.06%)
T   28.26 (+1.33%)
F   11.98 (+2.39%)
ACB   11.32 (+7.60%)
DIS   195.67 (+3.51%)
BA   224.80 (+6.03%)
NFLX   550.43 (+2.15%)
BAC   35.63 (+2.65%)
Log in
OTCMKTS:ALPMY

Astellas Pharma Competitors

$15.87
-0.66 (-3.96 %)
(As of 02/26/2021 08:28 PM ET)
Add
Compare
Today's Range
$15.43
Now: $15.87
$16.21
50-Day Range
$15.53
MA: $16.49
$17.41
52-Week Range
$12.48
Now: $15.87
$18.43
Volume46,200 shs
Average Volume82,368 shs
Market Capitalization$29.54 billion
P/E Ratio22.99
Dividend Yield1.83%
Beta0.63

Competitors

Astellas Pharma (OTCMKTS:ALPMY) Vs. SNY, CSLLY, GSK, ZTS, BAYRY, and VRTX

Should you be buying ALPMY stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Astellas Pharma, including Sanofi (SNY), CSL (CSLLY), GlaxoSmithKline (GSK), Zoetis (ZTS), Bayer Aktiengesellschaft (BAYRY), and Vertex Pharmaceuticals (VRTX).

Sanofi (NASDAQ:SNY) and Astellas Pharma (OTCMKTS:ALPMY) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Dividends

Sanofi pays an annual dividend of $1.17 per share and has a dividend yield of 2.5%. Astellas Pharma pays an annual dividend of $0.29 per share and has a dividend yield of 1.8%. Sanofi pays out 35.2% of its earnings in the form of a dividend. Astellas Pharma pays out 30.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Institutional & Insider Ownership

6.9% of Sanofi shares are owned by institutional investors. Comparatively, 0.2% of Astellas Pharma shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Sanofi and Astellas Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sanofi$40.00 billion2.90$3.26 billion$3.3213.90
Astellas Pharma$11.97 billion2.47$1.80 billion$0.9616.53

Sanofi has higher revenue and earnings than Astellas Pharma. Sanofi is trading at a lower price-to-earnings ratio than Astellas Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Sanofi and Astellas Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sanofi14402.33
Astellas Pharma00103.00

Profitability

This table compares Sanofi and Astellas Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sanofi14.49%24.77%13.28%
Astellas Pharma11.03%13.24%7.89%

Risk & Volatility

Sanofi has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Astellas Pharma has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.

Summary

Sanofi beats Astellas Pharma on 11 of the 15 factors compared between the two stocks.

CSL (OTCMKTS:CSLLY) and Astellas Pharma (OTCMKTS:ALPMY) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Dividends

CSL pays an annual dividend of $0.97 per share and has a dividend yield of 0.9%. Astellas Pharma pays an annual dividend of $0.29 per share and has a dividend yield of 1.8%. CSL pays out 42.0% of its earnings in the form of a dividend. Astellas Pharma pays out 30.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Astellas Pharma is clearly the better dividend stock, given its higher yield and lower payout ratio.

Institutional & Insider Ownership

0.2% of CSL shares are owned by institutional investors. Comparatively, 0.2% of Astellas Pharma shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares CSL and Astellas Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CSL$9.15 billion10.21$2.10 billion$2.3144.43
Astellas Pharma$11.97 billion2.47$1.80 billion$0.9616.53

CSL has higher earnings, but lower revenue than Astellas Pharma. Astellas Pharma is trading at a lower price-to-earnings ratio than CSL, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for CSL and Astellas Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CSL03102.25
Astellas Pharma00103.00

Profitability

This table compares CSL and Astellas Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CSLN/AN/AN/A
Astellas Pharma11.03%13.24%7.89%

Risk & Volatility

CSL has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, Astellas Pharma has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.

Summary

Astellas Pharma beats CSL on 8 of the 13 factors compared between the two stocks.

GlaxoSmithKline (NYSE:GSK) and Astellas Pharma (OTCMKTS:ALPMY) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Valuation & Earnings

This table compares GlaxoSmithKline and Astellas Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GlaxoSmithKline$43.10 billion1.97$5.93 billion$3.1710.67
Astellas Pharma$11.97 billion2.47$1.80 billion$0.9616.53

GlaxoSmithKline has higher revenue and earnings than Astellas Pharma. GlaxoSmithKline is trading at a lower price-to-earnings ratio than Astellas Pharma, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

GlaxoSmithKline has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Astellas Pharma has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.

Institutional & Insider Ownership

11.8% of GlaxoSmithKline shares are owned by institutional investors. Comparatively, 0.2% of Astellas Pharma shares are owned by institutional investors. 10.0% of GlaxoSmithKline shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares GlaxoSmithKline and Astellas Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GlaxoSmithKline18.50%29.60%7.11%
Astellas Pharma11.03%13.24%7.89%

Analyst Ratings

This is a summary of recent recommendations for GlaxoSmithKline and Astellas Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GlaxoSmithKline33602.25
Astellas Pharma00103.00

Dividends

GlaxoSmithKline pays an annual dividend of $2.48 per share and has a dividend yield of 7.3%. Astellas Pharma pays an annual dividend of $0.29 per share and has a dividend yield of 1.8%. GlaxoSmithKline pays out 78.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Astellas Pharma pays out 30.2% of its earnings in the form of a dividend. GlaxoSmithKline has raised its dividend for 1 consecutive years. GlaxoSmithKline is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

GlaxoSmithKline beats Astellas Pharma on 11 of the 16 factors compared between the two stocks.

Zoetis (NYSE:ZTS) and Astellas Pharma (OTCMKTS:ALPMY) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Earnings & Valuation

This table compares Zoetis and Astellas Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zoetis$6.26 billion11.99$1.50 billion$3.6443.38
Astellas Pharma$11.97 billion2.47$1.80 billion$0.9616.53

Astellas Pharma has higher revenue and earnings than Zoetis. Astellas Pharma is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Zoetis has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Astellas Pharma has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.

Institutional & Insider Ownership

92.5% of Zoetis shares are held by institutional investors. Comparatively, 0.2% of Astellas Pharma shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Zoetis and Astellas Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zoetis25.50%63.89%14.99%
Astellas Pharma11.03%13.24%7.89%

Analyst Recommendations

This is a summary of recent ratings for Zoetis and Astellas Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zoetis07702.50
Astellas Pharma00103.00

Zoetis presently has a consensus target price of $167.7273, suggesting a potential upside of 7.35%. Given Zoetis' higher probable upside, analysts plainly believe Zoetis is more favorable than Astellas Pharma.

Dividends

Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.6%. Astellas Pharma pays an annual dividend of $0.29 per share and has a dividend yield of 1.8%. Zoetis pays out 27.5% of its earnings in the form of a dividend. Astellas Pharma pays out 30.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 1 consecutive years.

Summary

Zoetis beats Astellas Pharma on 13 of the 17 factors compared between the two stocks.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) and Astellas Pharma (OTCMKTS:ALPMY) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Earnings & Valuation

This table compares Bayer Aktiengesellschaft and Astellas Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bayer Aktiengesellschaft$48.23 billion1.18$4.58 billion$1.778.64
Astellas Pharma$11.97 billion2.47$1.80 billion$0.9616.53

Bayer Aktiengesellschaft has higher revenue and earnings than Astellas Pharma. Bayer Aktiengesellschaft is trading at a lower price-to-earnings ratio than Astellas Pharma, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Bayer Aktiengesellschaft has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Astellas Pharma has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.

Institutional & Insider Ownership

0.2% of Astellas Pharma shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Bayer Aktiengesellschaft and Astellas Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bayer Aktiengesellschaft-22.32%14.23%5.01%
Astellas Pharma11.03%13.24%7.89%

Analyst Recommendations

This is a summary of recent ratings for Bayer Aktiengesellschaft and Astellas Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bayer Aktiengesellschaft17602.36
Astellas Pharma00103.00

Dividends

Bayer Aktiengesellschaft pays an annual dividend of $0.53 per share and has a dividend yield of 3.5%. Astellas Pharma pays an annual dividend of $0.29 per share and has a dividend yield of 1.8%. Bayer Aktiengesellschaft pays out 29.9% of its earnings in the form of a dividend. Astellas Pharma pays out 30.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bayer Aktiengesellschaft is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Bayer Aktiengesellschaft beats Astellas Pharma on 8 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Astellas Pharma (OTCMKTS:ALPMY) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Insider and Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.2% of Astellas Pharma shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Vertex Pharmaceuticals and Astellas Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals042312.89
Astellas Pharma00103.00

Vertex Pharmaceuticals presently has a consensus target price of $291.8462, suggesting a potential upside of 37.06%. Given Vertex Pharmaceuticals' higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Astellas Pharma.

Volatility & Risk

Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Astellas Pharma has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.

Earnings and Valuation

This table compares Vertex Pharmaceuticals and Astellas Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.28$1.18 billion$4.2949.59
Astellas Pharma$11.97 billion2.47$1.80 billion$0.9616.53

Astellas Pharma has higher revenue and earnings than Vertex Pharmaceuticals. Astellas Pharma is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vertex Pharmaceuticals and Astellas Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Astellas Pharma11.03%13.24%7.89%

Summary

Vertex Pharmaceuticals beats Astellas Pharma on 12 of the 15 factors compared between the two stocks.


Astellas Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sanofi logo
SNY
Sanofi
1.6$46.15-0.6%$114.91 billion$40.00 billion19.72
CSL logo
CSLLY
CSL
1.0$102.64-2.7%$93.40 billion$9.15 billion44.43Increase in Short Interest
Gap Up
GlaxoSmithKline logo
GSK
GlaxoSmithKline
1.1$33.82-0.6%$84.31 billion$43.10 billion10.41Increase in Short Interest
Zoetis logo
ZTS
Zoetis
2.1$157.92-1.7%$73.76 billion$6.26 billion46.86
Bayer Aktiengesellschaft logo
BAYRY
Bayer Aktiengesellschaft
1.0$15.30-2.7%$57.07 billion$48.23 billion-5.71Analyst Report
Increase in Short Interest
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$212.73-0.1%$55.25 billion$4.16 billion26.86Analyst Upgrade
Takeda Pharmaceutical logo
TAK
Takeda Pharmaceutical
2.0$16.98-1.6%$52.68 billion$30.20 billion56.60
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$462.14-2.5%$48.27 billion$7.86 billion16.89Analyst Report
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.9$153.18-0.3%$33.58 billion$4.99 billion35.79Increase in Short Interest
Shiseido logo
SSDOY
Shiseido
0.9$75.28-0.5%$30.07 billion$10.38 billion-259.59Increase in Short Interest
BeiGene logo
BGNE
BeiGene
1.1$319.66-0.1%$29.27 billion$428.21 million-15.82Earnings Announcement
Analyst Downgrade
Analyst Revision
Takeda Pharmaceutical logo
TKPYY
Takeda Pharmaceutical
1.0$16.71-0.2%$26.11 billion$15.99 billion12.11
Genmab A/S logo
GMAB
Genmab A/S
1.5$34.90-3.0%$22.20 billion$804.57 million27.05Earnings Announcement
Analyst Downgrade
Increase in Short Interest
Analyst Revision
Gap Down
Genmab A/S logo
GNMSF
Genmab A/S
0.6$331.00-4.2%$21.28 billion$804.57 million4.70Increase in Short Interest
News Coverage
Gap Down
MKGAF
MERCK Kommanditgesellschaft auf Aktien
0.5$163.50-2.3%$21.13 billion$18.09 billion0.00Upcoming Earnings
UCB logo
UCBJF
UCB
1.0$106.85-0.0%$20.78 billion$5.50 billion18.36News Coverage
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$91.19-0.3%$20.06 billion$1.30 billion24.92Earnings Announcement
Insider Selling
Catalent logo
CTLT
Catalent
1.5$115.29-1.4%$19.36 billion$3.09 billion73.43
Royalty Pharma logo
RPRX
Royalty Pharma
1.4$47.94-2.9%$18.08 billionN/A0.00Insider Buying
Gap Down
CureVac logo
CVAC
CureVac
0.6$96.14-1.9%$17.63 billionN/A0.00Decrease in Short Interest
Gap Down
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$148.87-0.5%$17.33 billion$219.75 million-19.01Analyst Report
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$33.28-1.3%$15.51 billion$3.07 billion-58.39Earnings Announcement
Analyst Upgrade
Unusual Options Activity
Analyst Revision
OPHLF
Ono Pharmaceutical
1.1$29.70-0.0%$15.27 billion$2.69 billion27.00Upcoming Earnings
Increase in Short Interest
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$78.60-1.5%$14.06 billion$1.70 billion17.99Earnings Announcement
Analyst Report
Gap Down
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.4$10.95-1.7%$11.75 billion$16.89 billion-2.98
Grifols logo
GRFS
Grifols
1.2$16.43-1.0%$11.18 billion$5.71 billion14.67
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$31.95-1.7%$11.16 billion$8.60 billion-5.86Earnings Announcement
Analyst Report
Analyst Revision
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
1.6$71.01-0.5%$10.52 billion$40.56 million-20.82Earnings Announcement
Analyst Revision
Gap Down
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.2$204.84-1.9%$10.10 billion$3.34 million-26.60Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.5$60.68-1.2%$9.94 billion$2.32 billion50.15
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.2$141.49-0.0%$9.48 billion$103.71 million-32.23
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$168.06-0.0%$9.46 billion$2.16 billion53.02Earnings Announcement
Analyst Report
Unusual Options Activity
Analyst Revision
Zai Lab logo
ZLAB
Zai Lab
1.2$157.60-6.4%$8.57 billion$12.98 million-52.01News Coverage
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.3$155.00-0.0%$8.28 billion$14.98 million-18.88
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.3$83.50-4.6%$8.27 billion$87.99 million-99.40Gap Down
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.8$48.93-0.1%$7.79 billion$339.08 million-28.45Earnings Announcement
Analyst Revision
News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.7$168.43-0.7%$7.43 billion$1.45 billion15.93Earnings Announcement
Analyst Report
Analyst Revision
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.4$54.33-3.6%$7.33 billion$1.12 billion113.19Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Schrödinger logo
SDGR
Schrödinger
1.3$110.18-7.0%$7.12 billion$85.54 million0.00Upcoming Earnings
Gap Down
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$86.51-0.6%$6.87 billion$380.83 million-11.06Analyst Report
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$215.00-0.3%$6.65 billion$311.33 million-125.00Decrease in Short Interest
Evotec logo
EVTCY
Evotec
0.5$77.45-0.8%$6.42 billion$500.07 million430.32High Trading Volume
Allakos logo
ALLK
Allakos
1.7$122.05-0.7%$6.36 billionN/A-44.54Upcoming Earnings
Analyst Revision
News Coverage
Gap Down
AVIR
Atea Pharmaceuticals
1.7$75.14-0.3%$6.23 billionN/A0.00Decrease in Short Interest
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$44.96-2.6%$5.76 billion$150,000.00-21.21Upcoming Earnings
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$98.60-0.4%$5.69 billion$66.51 million18.19
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.9$119.49-1.3%$5.68 billionN/A-34.04Analyst Downgrade
Perrigo logo
PRGO
Perrigo
2.6$42.88-5.9%$5.51 billion$4.84 billion-714.55Earnings Announcement
Dividend Increase
Unusual Options Activity
Gap Down
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.9$35.56-8.5%$5.48 billionN/A0.00Upcoming Earnings
Analyst Report
News Coverage
Gap Down
Galapagos logo
GLPG
Galapagos
1.3$83.99-1.7%$5.40 billion$1.00 billion-12.73
This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.